140 related articles for article (PubMed ID: 37130750)
21. Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis.
Blažek T; Petráš M; Knybel L; Cvek J; Soumarová R
JAMA Netw Open; 2023 Mar; 6(3):e236324. PubMed ID: 37000447
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
[TBL] [Abstract][Full Text] [Related]
23. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
24. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Wang C; Yu X; Wang W
Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
[TBL] [Abstract][Full Text] [Related]
25. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
26. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.
Huang Y; Shen A
Medicine (Baltimore); 2020 Aug; 99(34):e21718. PubMed ID: 32846790
[TBL] [Abstract][Full Text] [Related]
27. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Li S; Chen L; Jiang J
Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
[TBL] [Abstract][Full Text] [Related]
28. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
Li J; Wang P; Xu Y
PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Xia H; Shen J; Hu F; Chen S; Huang H; Xu Y; Ma H
Clin Chim Acta; 2017 Jun; 469():191-194. PubMed ID: 28188721
[TBL] [Abstract][Full Text] [Related]
31. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis.
Shen X; Huang S; Xiao H; Zeng S; Liu J; Ran Z; Xiong B
Eur J Hosp Pharm; 2023 Jan; 30(1):3-8. PubMed ID: 34497128
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma.
Wotman M; Herman SW; Costantino P; Tham T
Laryngoscope; 2020 Nov; 130(11):2598-2606. PubMed ID: 32112431
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis.
Ma G; Deng Y; Jiang H; Li W; Wu Q; Zhou Q
Clin Chim Acta; 2018 Jul; 482():101-107. PubMed ID: 29614306
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
39. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.
Fitzsimmons TS; Singh N; Walker TDJ; Newton C; Evans DGR; Crosbie EJ; Ryan NAJ
Front Med (Lausanne); 2023; 10():1192762. PubMed ID: 37250628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]